Molecular Targeted Cancer Therapies - More drugs on the market, more targets in the pipeline

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-10-10

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Cancer treatment continues to embrace the inclusion of molecular targeted therapies (MTT) into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.


Scope

  • Seven major pharmaceutical market sales forecasts from 2005 to 2015 for approved molecular targeted therapies and key pipeline candidates
  • Review of the current targeted therapies market, including profiles, product-specific assumptions and events over the forecasted period
  • Research and analysis of the targeted therapies pipeline with in-depth clinical and commercial assessment of Phase III candidates, plus expert opinion
  • Examination of product pipeline by phase, mode of action, indication, drug class and developer, plus two commercial impact case studies


    • Report Highlights
    In 2005, the MTT market was worth $7.5 billion and the forecast sales of already marketed drugs in this class are expected to grow to $25.2 billion by 2015, at a CAGR of 12.9%. This growth will be driven mainly by Genentech/Roche's Rituxan, Herceptin and Avastin as well as Novartis' Gleevec, all of which have already reached blockbuster status.

    274 different pipeline MTTs have been identified. The introduction of current late-phase candidates, including the pre-registered agents Tykerb (lapatinib; GlaxoSmithKline) and Zolinza (vorinostat; Merck), will further increase the market's total value by $3.8 billion, enabling the targeted therapies market to reach $29.1 billion in 2015.

    The rise in cost of cancer treatment is unsustainable with growing pharmacoeconomic pressures challenging healthcare payers globally. To counter these hurdles, developers must become more effective at communicating the value of their products. To this end, a comprehensive understanding of the targeted therapies market and pipeline is critical.


    Reasons to Purchase

  • Acquire a detailed appreciation and impartial perspective of the targeted cancer therapies market as a whole
  • Consider and react to the specific events influencing the future potential of marketed and pipeline targeted therapies
  • Gain an insight into the emerging clinical, developmental and commercial challenges and opportunities facing key developmental and marketed MTT drugs

    • Table of Contents

    Other users found this report page using the following search terms: targeted therapy Rituxan Herceptin Avastin gleevec laptinib sorafinib kinase vorinostat hdac ppt cancer targeted market therapy ofatumumab drugs therapies action mechanism

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.